☆ 4.7 Meeting Abstract

Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment

JOURNAL OF CLINICAL ONCOLOGY (2015)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 33, Issue 3, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/jco.2015.33.3_suppl.412

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma

Ilaria Trestini, Luisa Carbognin, Umberto Peretti, Isabella Sperduti, Alberto Caldart, Daniela Tregnago, Alice Avancini, Alessandra Auriemma, Giulia Orsi, Sara Pilotto, Luca Frulloni, Gabriele Capurso, Emilio Bria, Michele Reni, Giampaolo Tortora, Michele Milella

Summary: This retrospective study investigated the use of pancreatic enzyme replacement therapy (PERT) in advanced pancreatic ductal adenocarcinoma (PDAC) patients undergoing chemotherapy, and found that PERT was associated with significantly prolonged survival and alleviation of maldigestion-related symptoms.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Avital Klein-Brill, Shlomit Amar-Farkash, Gabriella Lawrence, Eric A. Collisson, Dvir Aran

Summary: This study compared the two common first-line treatments for metastatic adenocarcinoma of the pancreas, FOLFIRINOX and gemcitabine plus nab-paclitaxel, and found that FOLFIRINOX was associated with improved overall survival and fewer posttreatment complications.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Hematology

Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel

Jakob M. Riedl, Esther Schwarzenbacher, Florian Moik, Lena Horvath, Antonia Gantschnigg, Felix Renneberg, Florian Posch, Dominik A. Barth, Michael Stotz, Martin Pichler, Stefan Hatzl, Simon Fandler-Hofler, Paul Gressenberger, Thomas Gary, Philipp J. Jost, Richard Greil, Cihan Ay, Angela Djanani, Armin Gerger, Konstantin Schlick

Summary: This study aimed to comprehensively characterize the incidence, risk factors, and outcomes of VTE and ATE in aPC patients undergoing palliative first-line chemotherapy. Results showed that VTE diagnosis was associated with increased mortality and cancer progression risk, while the impact of ATE on mortality was numerically but not statistically significant.

THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Letter Oncology

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study

Shuling Chen, Jiaxin Li, Aoran Dong, Zelong Liu, Meiyan Zhu, Meng Jin, Guangyan Wei, Shuang Wu, Yan Wang, Yong Chen, Zhenwei Peng

Summary: This study compared the efficacy and safety of combination therapy with immunotherapy and radiotherapy versus chemotherapy alone for patients with locally advanced pancreatic adenocarcinoma (LAPC). The combination treatment group showed significant advantages in median overall survival and progression-free survival compared to the chemotherapy alone group. However, the incidence of severe adverse events did not differ significantly between the two groups. Therefore, combination therapy appears to be an effective and safe treatment option for LAPC patients.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

Add to Collection

Article Oncology

Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer

Takafumi Mie, Takashi Sasaki, Tsuyoshi Takeda, Takeshi Okamoto, Tsuyoshi Hamada, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Takaaki Furukawa, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, Naoki Sasahira

Summary: There is no established standard second-line chemotherapy for unresectable pancreatic cancer after modified FOLFIRINOX. The effectiveness and prognostic factors of gemcitabine plus nab-paclitaxel as second-line chemotherapy have been unclear. This study found that the median overall survival and progression-free survival of gemcitabine plus nab-paclitaxel as second-line treatment were 7.2 months and 3.6 months, respectively. Performance status, modified Glasgow prognostic score, and neutrophil-to-lymphocyte ratio were independent predictors of overall survival.

CANCERS (2023)

Add to Collection

Review Oncology

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine

Francesco Di Costanzo, Federica Di Costanzo, Lorenzo Antonuzzo, Ernesto Mazza, Elisa Giommoni

Summary: Choosing the best first-line treatment for metastatic pancreatic cancer is crucial in improving survival rate and quality of life. FOLFIRINOX and Nab-p plus Gem have been recognized as the most effective treatment regimens. FOLFIRINOX shows better efficacy but higher toxicity.

CANCERS (2023)

Add to Collection

Article Oncology

Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis

Jakob M. Riedl, Florian Posch, Lena Horvath, Antonia Gantschnigg, Felix Renneberg, Esther Schwarzenbacher, Florian Moik, Dominik A. Barth, Christopher H. Rossmann, Michael Stotz, Renate Schaberl-Moser, Martin Pichler, Herbert Stoger, Richard Greil, Angela Djanani, Konstantin Schlick, Armin Gerger

Summary: This study found that FOLFIRINOX and GN have similar effectiveness in the palliative first-line treatment of aPDAC. Despite some differences in patient characteristics between the two groups, survival outcomes remained comparable after weighting the data with propensity scores.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma

Sheron Perera, Gun Ho Jang, Yifan Wang, Deirdre Kelly, Michael Allen, Amy Zhang, Robert E. Denroche, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, Mustapha Tehfe, Ravi Ramjeesingh, James Biagi, Bernard Lam, Julie Wilson, Sandra E. Fischer, George Zogopoulos, Faiyaz Notta, Steven Gallinger, Robert C. Grant, Jennifer J. Knox, Grainne M. O'Kane

Summary: In advanced PDAC, hENT1 mRNA expression predicts ORR and OS in patients receiving GnP, while no association was observed in patients receiving mFFX.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer

Sam Z. Thalji, Mandana Kamgar, Ben George, Mohammed Aldakkak, Kathleen K. Christians, Callisia N. Clarke, Beth A. Erickson, William A. Hall, Parag P. Tolat, Zachary L. Smith, Douglas B. Evans, Susan Tsai

Summary: This study investigated the response of carbohydrate antigen 19-9 (CA19-9) to first-line and second-line chemotherapy in patients with operable pancreatic cancer. The study found that patients with no biochemical response after 2 months of first-line chemotherapy have a high rate of response to second-line chemotherapy.

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study

Yuan Zong, Jiajia Yuan, Zhi Peng, Ming Lu, Xicheng Wang, Lin Shen, Jun Zhou

Summary: The study compared the efficacy and safety of nab-paclitaxel plus S-1 with nab-paclitaxel plus gemcitabine in first-line chemotherapy for patients with PDAC. Despite comparable efficacy, the nab-P/S combination showed improved safety profile with reduced risks of hematological toxicity, liver injury, and rash. There were no significant differences in primary and secondary endpoints between the two treatment arms.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world

Norbert Marschner, Susanna Hegewisch-Becker, Marcel Reiser, Eyck von der Heyde, Mathias Bertram, Stephan H. Hollerbach, Stephan Kreher, Thomas Wolf, Adrian Binninger, Marco Chiabudini, Anja Kaiser-Osterhues, Martina Jaenicke

Summary: This study compares the real-world effectiveness and quality of life of first-line FOLFIRINOX and gemcitabine/nab-paclitaxel in patients with advanced pancreatic cancer. The Pancreatic Cancer Score (PCS) developed in this study indicates that only high-risk patients benefit from FOLFIRINOX treatment in terms of survival and overall QoL.

INTERNATIONAL JOURNAL OF CANCER (2023)

Add to Collection

Article Multidisciplinary Sciences

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer

Masaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, Taiga Otsuka, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Tomoyuki Ushijima, Keisuke Miwa, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Tsuyoshi Shirakawa

Summary: This study investigated the survival and efficacy of different chemotherapy regimens in patients with metastatic pancreatic cancer. The results showed that second-line chemotherapy was associated with longer overall survival compared to best supportive care. However, there was no significant difference in survival between combination chemotherapy and mono chemotherapy in the second-line treatment.

SCIENTIFIC REPORTS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer

Ilario Giovanni Rapposelli, Andrea Casadei-Gardini, Caterina Vivaldi, Giulia Bartolini, Laura Bernardini, Alessandro Passardi, Giovanni Luca Frassineti, Valentina Massa, Alessandro Cucchetti

Summary: The study found that FFX and GN have equivalent efficacy in first-line treatment of metastatic pancreatic cancer, but differ in safety profiles. Anemia was more frequent in the GN group, while higher occurrences of vomiting and diarrhea were reported in the FFX group.

BIOMOLECULES (2021)

Add to Collection

Article Oncology

Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study

Nicolas Williet, Angelica Petrillo, Gael Roth, Michele Ghidini, Mila Petrova, Julien Forestier, Anthony Lopez, Audrey Thoor, Lucie Weislinger, Ferdinando De Vita, Julien Taieb, Jean Marc Phelip

Summary: Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX (FFX) were found to have no significant difference as first-line treatments in patients with locally advanced pancreatic cancer (LAPC) in terms of survival, tumor response, or tumor resection rate, according to a multicenter European study. Further trials are needed to confirm these findings.

CANCERS (2021)

Add to Collection

Article Oncology

Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry

Jordan Santucci, Mark Tacey, Benjamin Thomson, Michael Michael, Rachel Wong, Julia Shapiro, Ross Jennens, Kate Clarke, Sharon Pattison, Matthew Burge, Rob Zielinski, Mehrdad Nikfarjam, Sumitra Ananda, Lara Lipton, Peter Gibbs, Belinda Lee

Summary: There was no significant difference in overall survival between first-line chemotherapy regimens of Gemcitabine/Nab-Paclitaxel and FOLFIRINOX in advanced pancreatic ductal adenocarcinoma (PDAC). However, FOLFIRINOX was associated with delayed disease progression.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Review Biochemistry & Molecular Biology

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes

Andrea Palicelli, Stefania Croci, Alessandra Bisagni, Eleonora Zanetti, Dario De Biase, Beatrice Melli, Francesca Sanguedolce, Moira Ragazzi, Magda Zanelli, Alcides Chaux, Sofia Canete-Portillo, Maria Paola Bonasoni, Stefano Ascani, Antonio De Leo, Guido Giordano, Matteo Landriscina, Giuseppe Carrieri, Luigi Cormio, Jatin Gandhi, Davide Nicoli, Enrico Farnetti, Simonetta Piana, Alessandro Tafuni, Martina Bonacini

Summary: This study reviewed the potential correlations between PD-L1 and MMR/MSI/BRCA/PTEN statuses in prostate cancer and discussed several other relevant genes. The results showed that some patients can be treated with specific antibody drugs. Further research is needed to verify the efficacy of these treatment methods and the relationship with the related factors.

BIOMEDICINES (2022)

Add to Collection

Article Oncology

Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis

Alessandro Parisi, Riccardo Giampieri, Alex Mammarella, Cristiano Felicetti, Lisa Salvatore, Maria Bensi, Maria Grazia Maratta, Antonia Strippoli, Roberto Filippi, Maria Antonietta Satolli, Angelica Petrillo, Bruno Daniele, Michele De Tursi, Pietro Di Marino, Guido Giordano, Matteo Landriscina, Pasquale Vitale, Ina Valeria Zurlo, Emanuela Dell'Aquila, Silverio Tomao, Ilaria Depetris, Francesca Romana Di Pietro, Federica Zoratto, Davide Ciardiello, Maria Vittoria Pensieri, Ornella Garrone, Barbara Galassi, Claudio Ferri, Rossana Berardi, Michele Ghidini

Summary: This study aimed to investigate the impact of primary and secondary chemotherapy-induced nausea and vomiting (CINV) prophylaxis with NK1 receptor antagonists (NK1-RA) in patients with gastrointestinal malignancies. The results showed that primary NK1-RA use reduced nausea and the need for rescue antiemetic therapy, and increased the rates of complete antiemetic response and complete antiemetic protection during chemotherapy.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era

Augusto Leone, Antonio Colamaria, Nicola Pio Fochi, Matteo Sacco, Matteo Landriscina, Giovanni Parbonetti, Matteo de Notaris, Giulia Coppola, Elena De Santis, Guido Giordano, Francesco Carbone

Summary: The current treatment guidelines for recurrent glioblastoma are still uncertain, and further research and clinical trials are needed to provide better treatment strategies. For patients who fail initial treatment and show signs of disease progression, clinicians need to consider the patient's medical history and molecular characteristics to develop personalized treatment plans.

BIOMEDICINES (2022)

Add to Collection

Article Oncology

Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)

Giulia Orsi, Alessandro Cavaliere, Giampaolo Tortora, Sara Lonardi, Marina Macchini, Mariacristina Di Marco, Guido Giordano, Enrico Vasile, Mario Scartozzi, Silvia Bozzarelli, Silvia Noventa, Maria Grazia Rodriquenz, Anna Maria Militello, Ilario Giovanni Rapposelli, Ingrid Garajova, Stefania De Lorenzo, Barbara Merelli, Alessandro Bittoni, Lisa Salvatore, Letizia Procaccio, Chiara Paratore, Andrea Spallanzani, Umberto Peretti, Monica Niger, Elisa Giommoni, Ilaria Bernardini, Emiliano Tamburini, Katia Bernardino, Laura Forti, Maria Maddalena Valente, Stefano Cascinu, Michele Milella, Michele Reni

Summary: This study demonstrates the beneficial role of platinum agents in PDAC patients with gBRCA1-2pv, both in second-line treatment and as part of early 3- and 4-drug platinum-based chemotherapy combinations, providing improved survival outcomes.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection

Review Oncology

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine

Francesco Di Costanzo, Federica Di Costanzo, Lorenzo Antonuzzo, Ernesto Mazza, Elisa Giommoni

Summary: Choosing the best first-line treatment for metastatic pancreatic cancer is crucial in improving survival rate and quality of life. FOLFIRINOX and Nab-p plus Gem have been recognized as the most effective treatment regimens. FOLFIRINOX shows better efficacy but higher toxicity.

CANCERS (2023)

Add to Collection

Article Oncology

Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis

Rodolfo Sacco, Daryl Ramai, Raffaella Tortora, Giovan Giuseppe di Costanzo, Michela Emma Burlone, Mario Pirisi, Piera Federico, Bruno Daniele, Marianna Silletta, Paolo Gallo, Caterina Cocuzza, Maurizio Russello, Giuseppe Cabibbo, Gabriele Rancatore, Silvia Cesario, Gianluca Masi, Luca Marzi, Andrea Mega, Alessandro Granito, Giulia Pieri, Edoardo G. G. Giannini, Rosa Paolillo, Gennaro Gadaleta-Caldarola, Vincenzo Dadduzio, Guido Giordano, Luca Giacomelli, Simonetta Papa, Matteo Renzulli, Marcello Maida, Michele Ghidini, Mauro Borzio, Antonio Facciorusso

Summary: Hepatocellular carcinoma is the fifth most common cancer worldwide. Lenvatinib has proven to be an effective option for treating advanced diseases. Our study showed that patients with nonviral etiologies have longer survival than those with viral etiology, which is important for clinical decision-making.

CANCERS (2023)

Add to Collection

Article Oncology

An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer

Carlotta Antoniotti, Alessandra Boccaccino, Robert Seitz, Mirella Giordano, Aurelie Catteau, Daniele Rossini, Filippo Pietrantonio, Lisa Salvatore, Kimberly McGregor, Francesca Bergamo, Veronica Conca, Simone Leonetti, Federica Morano, Giorgio Papiani, Emiliano Tamburini, Maria Bensi, Sabina Murgioni, Douglas Teller Ross, Alessandro Passardi, Isabelle Boquet, Tyler J. Nielsen, Jerome Galon, Matthew Gordon Varga, Brock L. Schweitzer, Chiara Cremolini

Summary: The AtezoTRIBE phase II study shows that adding atezolizumab to first-line FOLFOXIRI plus bevacizumab can prolong progression-free survival in patients with metastatic colorectal cancer (mCRC), especially for those with proficient mismatch repair (pMMR). DetermaIO, a 27-gene expression signature, is able to predict the benefits of immune checkpoint inhibition in triple-negative breast cancer. In this analysis of AtezoTRIBE, the predictive impact of DetermaIO in mCRC was investigated.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Oncology

Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer

Guido Giordano, Raffaele Ivan Cincione, Francesca Losavio, Tiziano Senia, Arianna Aquilini Mummolo, Mario Pacilli, Vincenzo Lizzi, Giuseppina Bruno, Annamaria Piscazzi, Vincenza Conteduca, Matteo Landriscina

Summary: Patients with pancreatic cancer often suffer from malnutrition and significant weight loss, which negatively affect treatment outcomes. This study found that nutritional support and pancreatic enzyme replacement therapy can improve overall survival and nutritional parameters in patients with metastatic pancreatic cancer. Early and well-conducted nutritional support can positively impact survival and quality of life.

ONCOLOGIST (2023)

Add to Collection

Article Oncology

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma

Letizia Procaccio, Valeria Merz, Morena Fasano, Vanja Vaccaro, Elisa Giommoni, Andrea Pretta, Silvia Noventa, Maria Antonietta Satolli, Guido Giordano, Clizia Zichi, Carmine Pinto, Camilla Zecchetto, Giulia Barsotti, Ferdinando De Vita, Michele Milella, Lorenzo Antonuzzo, Mario Scartozzi, Alberto Zaniboni, Rosella Spadi, Simona Casalino, Francesca Bergamo, Chiara De Toni, Davide Melisi, Sara Lonardi

Summary: This study aimed to investigate the real-world efficacy and safety of 5-FU/LV-nal-IRI in advanced pancreatic ductal adenocarcinoma patients. The results showed that 5-FU/LV-nal-IRI demonstrated comparable efficacy and safety to NAPOLI-I trial in advanced pancreatic ductal adenocarcinoma patients.

CANCER MEDICINE (2023)

Add to Collection

Article Genetics & Heredity

Loss of Primary Cilia Potentiates BRAF/MAPK Pathway Activation in Rhabdoid Colorectal Carcinoma: A Series of 21 Cases Showing Ciliary Rootlet CoiledCoil (CROCC) Alterations

Andrea Remo, Federica Grillo, Luca Mastracci, Michele Simbolo, Matteo Fassan, Maria Paola Cecchini, Giuseppe Miscio, Antonio Sassano, Paola Parente, Alessandro Vanoli, Giovanna Sabella, Guido Giordano, Emanuele Damiano Urso, Luigi Cerulo, Aldo Scarpa, Francesco Fiorica, Massimo Pancione

Summary: A recent study explores the genetic and immunophenotypic characteristics of rhabdoid colorectal tumors (RCTs). The findings reveal that RCTs exhibit mismatch repair-deficient phenotypes, CK7-/CK20-/CDX2- marker phenotype, and aberrant activation of the MAPK pathway, particularly with BRAF V600E mutations. While SMARCB1/INI1 expression is normal, the ciliogenic markers CROCC and β-tubulin are globally altered in RCTs. Overall, these results indicate that primary ciliogenesis and MAPK pathway activation contribute to the aggressiveness of RCTs, suggesting a potential therapeutic target.

GENES (2023)

Add to Collection

Article Oncology

Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors

Claire Gallois, Matteo Landi, Julien Taieb, Marine Sroussi, Bahar Saberzadeh-Ardestani, Antoine Cazelles, Sara Lonardi, Francesca Bergamo, Rossana Intini, Giulia Maddalena, Filippo Pietrantonio, Francesca Corti, Margherita Ambrosini, Antonia Martinetti, Marco Maria Germani, Chiara Boccaccio, Guglielmo Vetere, Sophie Mouillet-Richard, Aurelien de Reynies, Frank A. Sinicrope, Chiara Cremolini, Pierre Laurent-Puig

Summary: In this study, a transcriptomic classification was used to identify three groups of microsatellite instability metastatic colorectal cancers (MSI mCRC) with different compositions of tumor microenvironment and proliferative capacities. The group with high stromal and low proliferation showed a poorer prognosis with immune checkpoint inhibitor treatment.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Health Care Sciences & Services

YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer

Maria Bencivenga, Lorena Torroni, Mariagiulia Dal Cero, Alberto Quinzii, Camilla Zecchetto, Valeria Merz, Simona Casalino, Francesco Taus, Silvia Pietrobono, Domenico Mangiameli, Federica Filippini, Mariella Alloggio, Claudia Castelli, Mar Iglesias, Manuel Pera, Davide Melisi

Summary: This study found that the activation of the YAP pathway is associated with poor prognosis in poorly cohesive gastric cancer, suggesting its important role in the development of this type of cancer.

JOURNAL OF PERSONALIZED MEDICINE (2023)

Add to Collection

Review Oncology

Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data

Guido Giordano, Gaia Griguolo, Matteo Landriscina, Icro Meattini, Francesco Carbone, Augusto Leone, Marzia Del Re, Stefano Fogli, Romano Danesi, Antonio Colamaria, Maria Vittoria Dieci

Summary: This article discusses the management strategies for HER2+ breast cancer brain metastases. Despite some therapeutic advances, there is still a need for more effective systemic treatment options. The article summarizes current and future locoregional and systemic strategies and proposes an evidence-based treatment algorithm.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2023)

Add to Collection

Meeting Abstract Oncology

Real-world impact of olaparib use in advanced pancreatic cancer (PC) patients (pts) harboring germline BRCA1/2 (gBRCA) mutations

M. Milella, G. Orsi, A. Palloni, L. Salvatore, L. Procaccio, S. Noventa, S. Bozzarelli, I. Garajova, E. Vasile, G. Giordano, M. Macchini, A. Cavaliere, M. Gaule, S. Lonardi, M. C. Di Marco, G. Tortora, I. Sperduti, M. Reni

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study

Alessandro Rizzo, Massimiliano Salati, Giorgio Frega, Valeria Merz, Francesco Caputo, Alessandro Di Federico, Andrea Palloni, Riccardo Carloni, Angela Dalia Ricci, Gennaro Gadaleta-Caldarola, Carlo Messina, Andrea Spallanzani, Fabio Gelsomino, Stefania Benatti, Gabriele Luppi, Davide Melisi, Massimo Dominici, Giovanni Brandi

Summary: The study suggests that second-line chemotherapy could be equally effective for patients aged >= 70 years old compared to younger patients, with similar survival outcomes. However, absolute lymphocyte count and albumin level were independently associated with worse prognoses.

MEDICINA-LITHUANIA (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.